Pfizer Ventures leads with Deep Track, GV and Aditum; the asset LBL-051 comes from Nanjing's Leads Biolabs, another China-discovered drug advanced through a US company
Global private capital deployed into drug development and health-technology companies, concentrated in the United States and Europe, funding the pipeline from which most new medicines emerge.